Recent news coverage relevant to Vaxart is primarily industry-focused with no direct company-specific operational updates in the latest period.

• Industry news highlights expanding Brazil coffee exports impacting Arabica prices [N1].
• Reports indicate ongoing losses in hog markets amid cash weakness [N2].
• Multiple Q3 2026 earnings call transcripts from various companies were published, providing broader market context but no direct Vaxart updates [N3][N4][N5][N6][N7][N8].

The company benefits from a specialized oral vaccine platform that could offer advantages in ease of administration and patient compliance. Its government contracts and collaborations provide revenue streams supporting ongoing R&D activities. Experienced management and board members with strong biotech backgrounds may facilitate successful clinical development and potential partnerships.

Vaxart operates at a net loss with significant R&D expenses, reflecting the high-risk nature of clinical-stage biotech ventures. The company depends heavily on government contracts and collaborations, which may be subject to variability. Clinical trial outcomes and regulatory hurdles pose execution risks. Liquidity, while adequate currently, requires careful management to sustain operations through development milestones.

Vaxart's moat is derived from its proprietary oral vaccine technology platform and its focus on infectious diseases, which may provide differentiation in vaccine delivery methods. The company's leadership team has significant industry experience, which supports strategic development and potential commercialization efforts. However, as a clinical-stage biotech company, it faces typical sector challenges including regulatory approvals, clinical trial success, and competition from established vaccine developers.

• Clinical Development Risk: The success of Vaxart depends on the outcomes of its clinical trials and regulatory approvals, which are inherently uncertain and may delay or prevent product commercialization.
• Financial Risk: The company reports net losses and relies on external funding sources, including government contracts and collaborations, to finance operations. Liquidity management is critical to sustain development activities.
• Market and Competitive Risk: Vaxart faces competition from established vaccine developers and emerging biotech firms, which may impact its market positioning and partnership opportunities.

• Vaxart, Inc. is a publicly traded company on the OTCQX Best Market under the ticker VXRT [S1].
• The company is incorporated in Delaware with principal executive offices in South San Francisco, CA [S1].
• As of September 30, 2026, Vaxart had approximately 243.8 million shares of common stock issued and 243.7 million shares outstanding [S2].
• The executive leadership team includes Steven Lo as President and CEO since March 2024, Jeroen Grasman as CFO since May 2025, Sean Tucker, Ph.D. as Chief Scientific Officer, Edward B. Berg as Senior VP and General Counsel, and James Cummings, M.D. as Chief Medical Officer [S1].
• The board of directors includes experienced industry professionals such as Kevin P. Finney, Elaine J. Heron, Ph.D., and W. Mark Watson, CPA [S1].
• Vaxart's business involves clinical-stage biotechnology and pharmaceutical development, with a focus on vaccines and infectious diseases, as indicated by the backgrounds of its executives and clinical trial references [S1].
• For the quarter ended September 30, 2026, the company reported total revenue of $10.62 million, including government contract revenue of $7.55 million and collaboration revenue of $2.92 million [S2].
• Operating expenses for the same period were $27.9 million, with research and development expenses of $22.8 million and general and administrative expenses of $5.1 million [S2].
• The company reported a net loss of $17.7 million for the quarter ended September 30, 2026, with basic net loss per share of $0.07 [S2].
• As of September 30, 2026, Vaxart had cash and cash equivalents of approximately $35.1 million and short-term investments of $30.4 million, with total current assets of $126.4 million and current liabilities of $73.9 million, resulting in a current ratio of 1.71 and a cash ratio of 0.55 [S2].
• The company has liabilities related to sale of future royalties and operating lease liabilities [S2].
• Recent news coverage includes industry and market-related articles but no direct company-specific operational updates in the latest period [N1][N2][N3][N4][N5][N6][N7][N8].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].